
SLEEP
Dayvigo (Lemborexant): How It Works, Dosage and Side Effects
How Dayvigo (lemborexant) works, how it's taken, what the SUNRISE trials found, its side effects, and how it compares with Belsomra, Quviviq and Ambien.

The Zest Team
· 5 min read
Dayvigo is the brand name for lemborexant, a prescription sleep medication from Eisai that the FDA approved in December 2019 for adults who have trouble falling asleep or staying asleep. It is a dual orexin receptor antagonist (DORA): it blocks orexin, the brain's "stay awake" signal, rather than sedating the whole brain the way Ambien and benzodiazepines do.
Here is how Dayvigo works, how it is taken, what the trials found, its side effects, and how it compares with Belsomra, Quviviq and Ambien. This is educational information, not medical advice; talk to a licensed clinician before starting or stopping any medication.
Dayvigo at a glance
| Generic name | Lemborexant |
|---|---|
| Brand name | Dayvigo (Eisai) |
| Drug class | Dual orexin receptor antagonist (DORA) |
| FDA approval | December 20, 2019, for adults with trouble falling asleep and/or staying asleep |
| Controlled substance | Yes, DEA Schedule IV |
| Strengths | 5 mg and 10 mg tablets |
| Usual dose | 5 mg immediately before bed, with at least 7 hours before waking; up to 10 mg based on response |
| Half-life | 17–19 hours (peak levels 1–3 hours after a dose) |
| Not for | People with narcolepsy |
How does Dayvigo work?
Orexin (also called hypocretin) is a signal made by a small group of brain cells that keeps you awake. It runs high in the day and falls at night. Lemborexant blocks both orexin receptors, OX1R and OX2R, which turns the wake signal down so your natural sleep drive can take over.
The older sleeping pills, such as Ambien (zolpidem) and benzodiazepines, work the other way: they boost GABA, the brain's main "brake," to sedate the brain broadly. For more on the DORA class, see our guide to DORAs and daridorexant (Quviviq).
How to take Dayvigo (dosage)
- The FDA label's recommended dose is 5 mg, no more than once a night, immediately before going to bed, with at least 7 hours left before you plan to wake.
- A prescriber can raise it to 10 mg based on response and tolerability. 10 mg is the maximum.
- Taking it with or soon after a meal can delay sleep onset.
- With moderate liver impairment the maximum is 5 mg; it is not recommended with severe liver impairment.
- Avoid it with strong or moderate CYP3A inhibitors (some antifungals, antibiotics and other medicines). With weak CYP3A inhibitors the maximum is 5 mg. Tell your prescriber everything you take.
- Do not combine it with alcohol or other sedatives.
Does Dayvigo work? What the trials found
Lemborexant was approved on two phase 3 trials known as SUNRISE-1 and SUNRISE-2.
- SUNRISE-1 (JAMA Network Open, 2019) enrolled 1,006 older adults (median age 63) for one month. Both doses helped people fall asleep faster and spend about 24–25 fewer minutes awake during the night than placebo, measured in a sleep lab. It also beat zolpidem extended-release on time awake in the second half of the night.
- SUNRISE-2 (Sleep, 2020) followed adults over six months. People on 5 mg and 10 mg reported falling asleep faster, waking less and sleeping more efficiently than with placebo, and the benefit held at six months. Most side effects were mild or moderate.
Dayvigo side effects
In the label's pooled data from the first 30 days of treatment:
| Side effect | Placebo | Dayvigo 5 mg | Dayvigo 10 mg |
|---|---|---|---|
| Sleepiness or fatigue | 1.3% | 6.9% | 9.6% |
| Headache | 3.4% | 5.9% | 4.5% |
| Nightmares or abnormal dreams | 0.9% | 0.9% | 2.2% |
Sleep paralysis was reported in 1.3% (5 mg) and 1.6% (10 mg) of people, versus none on placebo. Like the other DORAs, Dayvigo carries warnings about next-day impairment (the label cautions people on 10 mg against next-day driving), complex sleep behaviors such as sleep-walking, hallucinations around sleep, cataplexy-like weakness, and worsening depression or suicidal thoughts. Care is needed with breathing problems such as sleep apnea or COPD. Call your clinician if you notice any of these.

Dayvigo vs. Belsomra vs. Quviviq
| Medication | Approved | Half-life | Usual dose |
|---|---|---|---|
| Dayvigo (lemborexant) | 2019 | 17–19 hours | 5 mg (up to 10 mg) |
| Belsomra (suvorexant) | 2014 | About 12 hours | 10 mg (up to 20 mg) |
| Quviviq (daridorexant) | 2022 | About 8 hours | 25–50 mg |
All three are Schedule IV DORAs with the same class warnings. Dayvigo lasts longest, which can help with waking late in the night but raises the chance of morning grogginess for some people. See our guides to Belsomra (suvorexant) and Quviviq (daridorexant).

Dayvigo vs. Ambien
Ambien (zolpidem) is a GABA-based sleeping pill with a short half-life (about 2.5 hours for the immediate-release form) and a boxed warning for complex sleep behaviors. Dayvigo blocks the wake signal instead and carries no boxed warning. In SUNRISE-1, lemborexant reduced time awake in the second half of the night more than zolpidem extended-release did. Ambien is available as a generic; Dayvigo is not.
How to get Dayvigo prescribed
Dayvigo is a controlled substance and needs a prescription from a licensed clinician after an evaluation of your sleep, health and medications. Good sleep habits and cognitive behavioral therapy for insomnia (CBT-I) remain the first step; medication works best alongside them.
Zest RX for sleep. Zest is preparing to launch telehealth for sleep, connecting you with licensed providers who can evaluate whether a prescription option fits your needs. Join Zest RX early access.
Frequently asked questions
Is Dayvigo a controlled substance?
Yes. Lemborexant is a DEA Schedule IV controlled substance, like Belsomra, Quviviq and Ambien. It needs a prescription.
Yes. Lemborexant is a DEA Schedule IV controlled substance, like Belsomra, Quviviq and Ambien. It needs a prescription.
How long does Dayvigo last?
Lemborexant's half-life is 17–19 hours according to the FDA label, the longest of the three DORAs. That is why the label says to take it only with at least 7 hours left before waking.
Lemborexant's half-life is 17–19 hours according to the FDA label, the longest of the three DORAs. That is why the label says to take it only with at least 7 hours left before waking.
Is there a generic for Dayvigo?
No. Eisai's Dayvigo is the only lemborexant product approved in the United States, according to the FDA's Drugs@FDA database.
No. Eisai's Dayvigo is the only lemborexant product approved in the United States, according to the FDA's Drugs@FDA database.
Is Dayvigo better than Belsomra?
Neither is universally better. They work the same way; Dayvigo lasts longer and is taken at 5–10 mg, Belsomra at 10–20 mg. Which fits depends on your sleep pattern and health, a decision for your clinician.
Neither is universally better. They work the same way; Dayvigo lasts longer and is taken at 5–10 mg, Belsomra at 10–20 mg. Which fits depends on your sleep pattern and health, a decision for your clinician.
Does Dayvigo cause nightmares?
Nightmares or abnormal dreams were reported by 2.2% of people on 10 mg in the label's 30-day data, versus 0.9% on placebo and 0.9% on 5 mg.
Nightmares or abnormal dreams were reported by 2.2% of people on 10 mg in the label's 30-day data, versus 0.9% on placebo and 0.9% on 5 mg.
Who should not take Dayvigo?
People with narcolepsy should not take it, and it is not recommended with severe liver impairment. People with depression or breathing problems need extra care.
People with narcolepsy should not take it, and it is not recommended with severe liver impairment. People with depression or breathing problems need extra care.
Sources
- DAYVIGO (lemborexant) prescribing information, Eisai. DailyMed
- Rosenberg R, et al. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. JAMA Netw Open. 2019;2(12):e1918254. PubMed
- Kärppä M, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43(9). PubMed
SLEEP
INSOMNIA
SLEEP MEDICATION


